TY - JOUR
T1 - Weighing Potential Benefits and Harms of Mycoplasma genitalium Testing and Treatment Approaches
AU - Manhart, Lisa E.
AU - Geisler, William M.
AU - Bradshaw, Catriona S.
AU - Jensen, Jørgen S.
AU - Martin, David H.
N1 - Funding Information:
This work was supported by the National Institute of Allergy and Infectious Diseases at the National Institutes of Health (grant numbers R01AI110666, U19AI113173, R01AI61019 to L.E.M.) and by the US Centers for Disease Control and Prevention/DHHS (grant number NU62PS924587 to Nicholas Van Wagoner for W.M.G.).
Publisher Copyright:
© 2022 Centers for Disease Control and Prevention (CDC). All rights reserved.
PY - 2022/8
Y1 - 2022/8
N2 - Since Mycoplasma genitalium was identified 40 years ago, much of the epidemiology has been described, diagnostic tests have been developed and approved, and recommended treatment approaches have been identified. However, the natural history remains incompletely understood, and antimicrobial resistance has rapidly increased. This review summarizes evidence published since the US Centers for Disease Control and Prevention 2015 Sexually Transmitted Diseases Treatment Guidelines. Data on sequelae remain insufficient, macrolide resistance is common, and fluoroquinolone resistance is increasing. Potential benefits of testing and treatment include resolving symptoms, interrupting transmission, and preventing sequelae. Potential harms include cost, patient anxiety, and increasing antimicrobial resistance.
AB - Since Mycoplasma genitalium was identified 40 years ago, much of the epidemiology has been described, diagnostic tests have been developed and approved, and recommended treatment approaches have been identified. However, the natural history remains incompletely understood, and antimicrobial resistance has rapidly increased. This review summarizes evidence published since the US Centers for Disease Control and Prevention 2015 Sexually Transmitted Diseases Treatment Guidelines. Data on sequelae remain insufficient, macrolide resistance is common, and fluoroquinolone resistance is increasing. Potential benefits of testing and treatment include resolving symptoms, interrupting transmission, and preventing sequelae. Potential harms include cost, patient anxiety, and increasing antimicrobial resistance.
UR - https://www.scopus.com/pages/publications/85135282003
U2 - 10.3201/eid2808.220094
DO - 10.3201/eid2808.220094
M3 - Review Article
C2 - 35876565
AN - SCOPUS:85135282003
SN - 1080-6040
VL - 28
SP - E1-E11
JO - Emerging Infectious Diseases
JF - Emerging Infectious Diseases
IS - 8
ER -
